Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma

• Main Authors: Emeline Colomba (Author), Carolina Alves Costa Silva (Author), Gwénaël Le Teuff (Author), Jamie Elmawieh (Author), Daniel Afonso (Author), Axelle Benchimol‐Zouari (Author), Annalisa Guida (Author), Lisa Derosa (Author), Ronan Flippot (Author), Bruno Raynard (Author), Bernard Escudier (Author), François Bidault (Author), Laurence Albiges (Author)
• Format: Book
• Published: Wiley, 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background Cabozantinib, a standard of care metastatic renal cell carcinoma (mRCC), may be associated with weight and muscle loss. These effects of new generation VEGFR tyrosine kinase inhibitor on muscle mass loss are poorly described. Methods All cabozantinib‐treated mRCC patients from Ja...